Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on May 1, 2026. The filing discloses a significant regulatory milestone regarding the Company's lead product candidate, VEPPANU (vepdegestrant).
Key Financial Metrics and Material Changes
Regulatory Approval: The U.S. Food and Drug Administration (FDA) granted approval for VEPPANU for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer following disease progression on at least one line of endocrine-based therapy.
Financial Impact: Pursuant to a collaboration agreement with Pfizer Inc., the Company is entitled to receive a development milestone payment of $50.0 million upon FDA approval.
Offsets: The $50.0 million milestone payment will be offset by certain amounts owed to Yale University under an amended and restated license agreement dated June 18, 2024. The filing text does not provide a clear value for the specific offset amount.
Commercialization: The Company and Pfizer remain on track to announce the selection of a third-party commercialization partner. VEPPANU is noted as the first-and-only FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader.
Liquidity and Debt: The filing text does not provide a clear value for current revenue, profit, cash flow, margins, debt, or overall liquidity positions.
Guidance, Outlook, and Risks
Outlook: Management expects to proceed with the selection of a third party to commercialize VEPPANU. The FDA approval was received in advance of the Prescription Drug User Fee Act (PDUFA) date of June 5, 2026.
Risks and Contingencies: The filing contains forward-looking statements regarding the commercialization strategy and future operations. Actual results may differ materially due to risks discussed in the Company's quarterly and annual reports. The Company assumes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the exact amount of the offset payment owed to Yale University to determine the net cash inflow from the $50.0 million milestone.
- Monitor the timeline and identity of the third-party commercialization partner to be selected by Arvinas and Pfizer.
- Review the specific indications and limitations of the FDA approval for VEPPANU in the full press release (Exhibit 99.1).
- Assess the impact of this approval on the Company's overall cash runway and future revenue projections in upcoming quarterly filings.